Aged Causality Comorbidity Embolization Therapeutic/*statistics & numerical data Follow-Up Studies Humans Longitudinal Studies Lower Urinary Tract Symptoms/*epidemiology/*prevention & control Male Middle Aged Prostate/blood supply Prostatic Hyperplasia/diagnostic imaging/*epidemiology/*therapy Risk Factors Treatment Outcome

Aged Embolization Therapeutic Humans Lower Urinary Tract Symptoms/complications/therapy Male Prostate/blood supply/diagnostic imaging Prostatic Hyperplasia/complications/*therapy Treatment Outcome Bph Prostate artery embolisation Quality of life

Aged Humans Male Middle Aged *Patient Selection Prostate/surgery Prostatic Hyperplasia Quality of Life *Transurethral Resection of Prostate Treatment Outcome Urinary Bladder Neck Obstruction *Urodynamics

Adrenergic alpha-1 Receptor Antagonists Aged Humans Indoles Lower Urinary Tract Symptoms Male Naphthalenes Piperazines Prostatic Hyperplasia Quinazolines Randomized Controlled Trials as Topic Urological Agents

5-alpha Reductase Inhibitors/*adverse effects Drug Therapy Combination Ejaculation/drug effects Erectile Dysfunction/*chemically induced/drug therapy Finasteride Humans Libido/*drug effects Male Middle Aged Prostatic Hyperplasia/*drug therapy Randomized Controlled Trials as Topic *5α-Reductase Inhibitors *Erectile Dysfunction *Meta-Analysis *Sexual Dysfunction

Aged Humans Male Middle Aged Prostatic Hyperplasia/blood Prostatic Neoplasms/*blood Publication Bias Sensitivity and Specificity Zinc/*blood

Aged Blood Transfusion/statistics & numerical data Catheters Indwelling/statistics & numerical data Humans Laser Therapy Male Middle Aged Prospective Studies Prostatic Hyperplasia Randomized Controlled Trials as Topic Transurethral Resection of Prostate Treatment Outcome benign prostatic hyperplasia (BPH) prostate transurethral vaporesection transurethral resection of prostate (TURP)

Adrenergic alpha-1 Receptor Antagonists/*administration & dosage Adrenergic alpha-Antagonists Dose-Response Relationship Drug Humans Male Middle Aged Prostatic Hyperplasia *Quality of Life Sulfonamides/*administration & dosage Tamsulosin Prostatic hyperplasia alpha blockers

Humans Aged Cystectomy/methods *Urinary Bladder Neoplasms/surgery Urinary Bladder *Urinary Diversion/methods Hospital Mortality Bladder cancer Complications Epidemiology Mortality Radical cystectomy Urinary diversions

Aged Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/*pathology Female Humans Immune Checkpoint Inhibitors/*therapeutic use Liver Neoplasms/secondary Male Middle Aged Survival Analysis Urinary Bladder Neoplasms/*drug therapy/*pathology bladder cancer immune checkpoint inhibitors immunotherapy meta-analysis urothelial carcinoma

Aged Body Mass Index Cohort Studies Female Humans Longitudinal Studies Male Obesity/*complications Risk Factors Urinary Bladder Neoplasms/*etiology/pathology

Aged Cystectomy/adverse effects Humans Quality of Life Ureterostomy *Urinary Bladder Neoplasms/surgery *Urinary Diversion/adverse effects Cystectomy Systematic Review [Publication Type] Urinary Bladder Neoplasms

Adjuvants Immunologic/therapeutic use Administration Intravesical Aged BCG Vaccine/therapeutic use Humans *Mycobacterium bovis Neoplasm Invasiveness Neoplasm Recurrence Local *Urinary Bladder Neoplasms

Adult Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use B7-H1 Antigen/antagonists & inhibitors Carcinoma/*drug therapy/immunology/mortality/pathology Clinical Decision-Making Female Humans Immune Checkpoint Inhibitors/adverse effects/*therapeutic use Male Middle Aged Patient Selection Progression-Free Survival Time Factors Urinary Bladder Neoplasms/*drug therapy/immunology/mortality/pathology Urothelium/*drug effects/immunology/pathology Immune-checkpoint inhibitor Meta-analysis Programmed death-ligand 1 Urothelial carcinoma interests/personal relationships which may be considered as potential competing interests: The authors certify that all conflicts of interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the article are listed as follows: Shahrokh Shariat owns or co-owns the following patents: methods to determine prognosis after therapy for prostate cancer. Granted 2002-09-06. Methods to determine prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010-07-20. He has a consulting or advisory role for the following: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Jansen Lilly MSD Olympus Pfizer Pierre Fabre Roche Sanochemia Sanofi Takeda Urogen and Wolff. All remaining authors have declared no conflicts of interest.

Aged Aged 80 and over Female Humans Male Middle Aged Neoplasm Recurrence Local/*therapy Rhabdomyosarcoma/mortality/*therapy Survival Analysis Urinary Bladder Neoplasms/mortality/*therapy Adult Bladder Rhabdomyosarcoma

Adult Female *Hormones/adverse effects Humans Menopause Middle Aged Prospective Studies *Reproductive History Risk Factors *Urinary Bladder Neoplasms/epidemiology Bladder cancer Health Study Nurses’ females hormones reproductive factors

Aged Cystectomy/adverse effects/*methods/statistics & numerical data Humans Male Middle Aged Postoperative Complications Quality of Life Randomized Controlled Trials as Topic Robotic Surgical Procedures/adverse effects/*methods/statistics & numerical data Treatment Outcome Urinary Bladder Neoplasms/*surgery

Aged *Diet Dietary Fiber/*administration & dosage Female Humans Male Middle Aged Prospective Studies Risk Factors Urinary Bladder Neoplasms/*prevention & control *Whole Grains bladder cancer cohort study dietary fiber dose-response analysis grain

Aged *Brachytherapy Combined Modality Therapy Disease-Free Survival Female Humans Male Middle Aged Neoplasm Recurrence Local *Urinary Bladder Neoplasms/mortality/pathology/radiotherapy external beam radiotherapy interstitial brachytherapy muscle-invasive bladder cancer organ preservation

Aged Biomarkers/*blood C-Reactive Protein/analysis Cystectomy/*methods Female Humans Leukocyte Count Lymphocytes/pathology Male Middle Aged Neutrophils/pathology Platelet Count Preoperative Period Prognosis Proportional Hazards Models Retrospective Studies Urinary Bladder Neoplasms/blood/*mortality/*surgery Hematologic biomarker Meta-analysis Urothelial carcinoma of the bladder